In Oct 2007, the FDA declared that the labeling for all PDE5 inhibitors, which include tadalafil, needs a additional prominent warning from the potential threat of sudden hearing reduction as the result of submit-promoting studies of short term deafness connected to usage of PDE5 inhibitors.[19]Your web browser is no more supported by Microsoft. Up